Роль хламидий в этиологии воспалительных заболеваний органов малого таза

1. Igietseme J., Omosun Y., Stuchlik O., Reed M., Partin J., Qing H. et al. Role of epithelial-mesenchyme transition in Chlamydia pathogenesis. PLoS One. 2015; 10(12): e0145198.

2. Becker E., Hegemann J.H. All subtypes of the Pmp adhesin family are implicated in chlamydial virulence and show species-specific function. Microbiologyopen. 2014; 3(4): 544-56.

3. Klos A., Thalmann J., Peters J., Gérard H.C., Hudson A.P. The transcript profile of persistent Chlamydophila (Chlamydia) pneumoniae in vitro depends on the means by which persistence is induced. FEMS Microbiol. Lett. 2009; 291(1): 120-6.

4. Wood H., Fehlner-Gardner C., Berry J., Fischer E., Graham B., Hackstadt T. et al. Regulation of tryptophan synthase gene expression in Chlamydia trachomatis. Mol. Microbiol. 2003; 49(5): 1347-59.

5. Timms P., Good D., Wan C., Theodoropoulos C., Mukhopadhyay S., Summersgill J. et al. Differential transcriptional responses between the interferon-gamma-induction and iron-limitation models of persistence for Chlamydia pneumoniae. J. Microbiol. Immunol. Infect. 2009; 42(1): 27-37.

6. Amirshahi A., Wan C., Beagley K., Latter J., Symonds I., Timms P. Modulation of the Chlamydia trachomatis in vitro transcriptome response by the sex hormones estradiol and progesterone. BMC Microbiol. 2011; 11: 150.

7. Di Pietro M., Tramonti A., De Santis F., De Biase D., Schiavoni G., Filardo S. et al. Analysis of gene expression in penicillin G induced persistence of Chlamydia pneumoniae. J. Biol. Regul. Homeost. Agents. 2012; 26(2): 277-84.

8. Shima K., Kaufhold I., Eder T., Kading N., Schmidt N., Deenen R. et al. Diverse host-pathogen metabolism in reproductive and persistent Chlamydia trachomatis infection. In: Proceedings Eighth meeting of the European Society for Chlamydia Research. Oxford, United Kingdom September 6-9th 2016. Oxford; 2016: 9.

9. Hufnagel K., Lueong S., Willhauck-Fleckenstein M., Miao B., Michel A., Butt J. et al. Chlamydia trachomatis whole-proteome microarrays for antigenic target identification. In: Proceedings Eighth meeting of the European Society for Chlamydia Research. Oxford, United Kingdom September 6-9th 2016. Oxford; 2016: 9.

10. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2010. Atlanta, US: Department of Health and Human Services; 2011.

11. Geisler W.M., Morrison S.G., Doemland M.L., Iqbal S.M., Su J., Mancevski A. et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital Chlamydial infection. J. Infect. Dis. 2012; 206(12): 1836-43.

12. Budrys N.M., Gong S., Rodgers A.K., Wang J., Louden C., Shain R. et al. Chlamydia trachomatis antigens recognized by women with tubal factor infertility, normal fertility, and acute infection. Obstet. Gynecol. 2012; 119(5): 1009-16.

13. Steiner A.Z., Diamond M.P., Legro R.S., Schlaff W.D., Barnhart K.T., Casson P.R. et al. Chlamydia trachomatis IgG3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. Fertil. Steril. 2015; 104(6):1522-6.

14. Igietseme J.U., Omosun Y., Partin J., Goldstein J., He Q., Joseph K. et al. Prevention of Chlamydia – induced infertility by inhibition of local caspase activity. J. Infect. Dis. 2013; 207(7): 1095-104.

15. Yeruva L., Myers G.S., Spencer N., Creasy H.H., Adams N.E., Maurelli A.T. et al. Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. MBio. 2014; 5(3): e01241-14.

16. Gupta R., Arkatkar T., Yu J.J., Wali S., Haskins W.E., Chambers J.P. et al. Chlamydia muridarum infection associated host microRNAs in the murine genital tract and contribution to generation of host immune response. Am. J. Reprod. Immunol. 2015; 73(2): 126-40.

17. Shyu A.B., Wilkinson M.F., van Hoof A. Messenger RNA regulation: to translate or to degrade. EMBO J. 2008; 27(3): 471-81.

18. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014;15(3): 178-96.

19. Lee K., Nelson C.M. New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. Int. Rev. Cell. Mol. Biol. 2012; 294: 171-221.

20. Kothari A.N., Mi Z., Zapf M., Kuo P.C. Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clin. Transl. Med. 2014; 3: 35.

21. Yan J., Gumireddy K., Li A., Huang Q. Regulation of mesenchymal phenotype by microRNAs in cancer. Curr. Cancer Drug Targets. 2013; 13(9): 930-4.

22. Baud D., Thomas V., Arafa A., Regan L., Greub G. Waddlia chondrophila, a potential agent of human fetal death. Emerg. Infect. Dis. 2007; 13(8): 1239-43.

23. Baud D., Goy G., Osterheld M.C., Croxatto A., Borel N., Vial Y. et al. Role of Waddlia chondrophila placental infection in miscarriage. Emerg. Infect. Dis. 2014; 20(3): 460-4.

24. Goy G., Greub G. Antibiotic susceptibility of Waddlia chondrophila in acanthamoeba castellanii amoebae. Antimicrob. Agents Chemother. 2009; 53(6): 2663-6.

25. Hoenderboom B., van Oeffelen A., van Benthem B., van Bergen J., Ouburg S., Morre S., van den Broek I. The Netherlands Chlamydia cohort study (NECCST): risks of long-term complications after Chlamydia trachomatis infection in women, intermediate outcomes. In: Proceedings Eighth meeting of the European Society for Chlamydia Research. Oxford, United Kingdom September 6-9th 2016. Oxford; 2016: 63.

26. Mardh P.-A. A critical review on current knowledge on pelvic inflammatory disease (PID) with special reference to chlamydial infections. In: Proceedings Eighth meeting of the European Society for Chlamydia Research. Oxford, United Kingdom September 6-9th 2016. Oxford; 2016: 63.

27. Price M.J., Ades A.E., Soldan K., Welton N.J., Macleod J., Simms I. et al. The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. Health Technol. Assess. 2016; 20(22): 1-250.

28. van Ess E., Ouburg S., Dubrovina S., Morre S., Spaarganen J. The role of Chlamidya pneumonia (CP), Chlamydia trachomatis (CT) and CT genovars in women with lower abdominal pain (LAP). In: Proceedings Eighth meeting of the European Society for Chlamydia Research. Oxford, United Kingdom September 6-9th 2016. Oxford; 2016: 158.

29. Weström L., Joesoef R., Reynolds G., Hagdu A., Thompson S.E. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex. Transm. Dis. 1992; 19(4): 185-92.

30. British Association for Sexual Health and HIV (BASHH) Clinical Effectiveness Group. UK National guideline for the management of pelvic inflammatory disease 2011. Macclesfield: BASHH; 2011.

31. Horner P., Blee K., Adams E. Time to manage Mycoplasma genitalium as an STI: but not with azithromycin 1 g! Curr. Opin. Infect. Dis. 2014; 27(1): 68-74.

32. Workowski K.A., Berman S.; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm. Rep. 2010; 59(RR-12): 1-110.

33. Ades A.E., Price M.J, Kounali D., Akande V., Wills G., McClure M. et al. Proportion of Tubal Factor Infertility due to Chlamydia: finite mixture modeling of serum antibody titers. Am. J. Epidemiol. 2017; 185(2):124-34.

34. Geisler W.M., Suchland R.J., Whittington W.L., Stamm W.E. Quantitative culture of Chlamydia trachomatis: Relationship of inclusion-forming units produced in culture to clinical manifestations and acute inflammation in urogenital disease. J. Infect. Dis. 2001; 184(10): 1350-4.

35. Horner P.J., Wills G.S., Reynolds R., Johnson A.M., Muir D.A., Winston A. et al. Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study. Sex. Transm. Infect. 2013; 89(5): 398-403.

36. Schoeman S.A., Stewart C.M., Booth R.A., Smith S.D., Wilcox M.H., Wilson J.D. Assessment of best single sample for finding chlamydia in women with and without symptoms: a diagnostic test study. BMJ. 2012; 345: e8013.

37. Schoeman S., Stewart C., Wilson J. Menses - to test or not ot test? Sex. Transm. Infect. 2015; 91(Suppl. 1): A11.

38. Somani J., Bhullar V.B., Workowski K.A., Farshy C.E., Black C.M. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J. Infect. Dis. 2000; 181(4): 1421-7.

39. Bachmann L.H., Stephens J., Richey C.M., Hook E.W. 3rd. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex. Transm. Dis. 1999; 26(5): 272-8.

40. Khosropour C.M., Manhart L.E., Colombara D.V., Gillespie C.W., Lowens M.S., Totten P.A. et al. Suboptimal adherence to doxycycline and treatment outcomes among men with non-gonococcal urethritis: a prospective cohort study. Sex. Transm. Infect. 2014; 90(1): 3-7.

41. Lau C.Y., Qureshi A.K. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex. Transm. Dis. 2002; 29(9): 497-502.

42. Geisler W.M., Uniyal A., Lee J.Y., Lensing S.Y., Johnson S., Perry R.C. et al. Azithromycin versus doxycycline for urogenital Chlamydia trachomatis infection. N. Engl. J. Med. 2015; 373(26): 2512-21.

Поступила 16.12.2016

Принята в печать 23.12.2016